Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-26T17:51:03.675Z Has data issue: false hasContentIssue false
  • English
  • Français

Akathisia: Prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the multi-center FACE-SZ Dataset

Published online by Cambridge University Press:  23 March 2020

F. Berna ,
D. Misdrahi ,
L. Boyer ,
P.M. Llorca ,
G. Fond  and
W.G. Face-sz
F. Berna*
Affiliation:
Hôpitaux Universitaires de Strasbourg, Inserm U1114, FMTS, Fondation FondaMental, Psychiatry, Strasbourg cedex, France
D. Misdrahi
Affiliation:
Centre Hospitalier Charles-Perrens Bordeaux, CNRS UMR 5287, INCIA, Fondation FondaMental, Psychiatry, Bordeaux, France
L. Boyer
Affiliation:
CHU Sainte-Marguerite, Pôle Psychiatrie Universitaire, Marseille, France
P.M. Llorca
Affiliation:
CHU de Clermont-Ferrand, Fondation FondaMental, Psychiatry, Clermont-Ferrand, France
G. Fond
Affiliation:
Université Paris-Est, Inserm U955 eq15, GHU Mondor, DHU Pe-psy, Psychiatry, Créteil, France
W.G. Face-sz
Affiliation:
Université Paris-Est, Inserm U955 eq15, GHU Mondor, DHU Pe-psy, Psychiatry, Créteil, France
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The main objective of this study was to determine the prevalence of akathisia in a community-dwelling sample of patients with schizophrenia, and to determine the effects of treatments and the clinical variables associated with akathisia. Three hundred and seventy-two patients with schizophrenia or schizoaffective disorder were systematically included in the network of FondaMental Expert Center for Schizophrenia and assessed with validated scales. Akathisia was measured with the Barnes Akathisia Scale (BAS). Ongoing psychotropic treatment was recorded. The global prevalence of akathisia (as defined by a score of 2 or more on the global akathisia subscale of the BAS) in our sample was 18.5%. Patients who received antipsychotic polytherapy were at higher risk of akathisia and this result remained significant (adjusted odd ratio = 2.04, P = .025) after controlling the influence of age, gender, level of education, level of psychotic symptoms, substance use comorbidities, current administration of antidepressant, anticholinergic drugs, benzodiazepines, and daily-administered antipsychotic dose. Our results indicate that antipsychotic polytherapy should be at best avoided and suggest that monotherapy should be recommended in cases of akathisia. Long-term administration of benzodiazepines or anticholinergic drugs does not seem to be advisable in cases of akathisia, given the potential side effects of these medications.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
FC64
Information
European Psychiatry , Volume 33 , Issue S1: Abstracts of the 24th European Congress of Psychiatry , March 2016 , pp. S96 - S97
Copyright
Copyright © European Psychiatric Association 2016
Submit a response

Comments

No Comments have been published for this article.